Measurements The I-V characteristics of single-junction GaInNAs SC, for AM1.5G real-sun illumination, are shown in Figure 1a. Measurements were done with and without a 900-nm long-pass filter inserted before the SC. The filter was used for simulating the light absorption into top junctions present in a multijunction device. The open circuit voltage

(V oc) and short-circuit current (J sc) values for the GaInNAs SCs were 0.416 V and approximately 40 mA/cm2, and 0.368 V and approximately 10 mA/cm2, without and with a long-pass #Selleckchem Cyclopamine randurls[1|1|,|CHEM1|]# filter, respectively. The spectral behavior of PL and EQE is shown in Figure 1b. The bandgap of the GaInNAs was estimated from the PL peak maximum wavelength to be approximately 1 eV. Figure 1 The I – V characteristics of single-junction GaInNAs SC (a) and EQE and PL spectra of GaInNAs (b). Examples of the measured PL spectra for GaInNAsSb structures with different amounts of

Sb are presented in Figure 2a. As it can be seen, the bandgap of GaInNAsSb can be decreased down to 0.83 eV (1,500 nm). The I-V characteristics this website of a GaInNAsSb SC with E g = 0.9 eV measured under real sun excitation at AM1.5G are presented in Figure 2b. Figure 2 Measured photoluminescence spectra of GaInNAsSb SCs (a) and I – V characteristics of 0.9-eV GaInNAsSb SC (b). From the data presented in Figures 1 and 2b, we have calculated the W oc values for selected GaInNAs and GaInNAsSb single-junction SCs. For GaInNAs SC with E g = 1 eV the W oc was 0.58 V and for GaInNAsSb with E g = 0.90 eV, the W oc was 0.59 V. The best W oc we have achieved so far from GaInNAs single-junction SCs is 0.49 V [11]. Thiamine-diphosphate kinase The observations made here are in accordance with previously published reports which indicate that the Sb-based solar cells have a slightly higher W oc values compared to GaInNAs SCs [6, 9]. The J sc values at AM1.5G for GaInNAsSb solar cells are summarized in Table 1 together with calculated EQEav values for SCs with a thick GaAs filter. The fitted diode parameters for GaInNAsSb single-junction SCs are also included in Table 1.

The performance of the GaInP/GaAs/GaInNAs SC, which we used for initial estimation, was current limited to 12 mA/cm2[10]; we note here that 14 mA/cm2 would be needed for current matching with the two top junctions. Based on the J sc = 12 mA/cm2, we calculate that in our triple-junction SCs, the EQEav of GaInNAs subjunction below a thick GaAs filter is approximately 0.6. For the current matching of this particular type of triple-junction device, one would need an EQEav of 0.7. The V oc improvement from double- to triple-junction SC due to adding GaInNAs subjunction was 0.35 V. Using this information and our model, we can approximate the behavior of the pure GaInNAs subjunction at different illumination conditions. At 1/3 suns – situation which occurs when a lattice-matched triple-junction cell is illuminated by 1 sun – the W oc of GaInNAs subjunction is 0.56 V.

Table 1 Relationships between expression of VEGFR-2, PDGFR-β, and C-met and clinicopathological factors Tozasertib in vitro Palbociclib research buy Parameters N VEGFR-2 P PDGFR-β P C-MET P High Low High Low High Low N(%) 93 80(86.0) 13   18(19.4) 75   75(80.6) 18   Gender                     Male 77 69(89.6) 8   15(19.5) 62   61(79.2) 16   Female 16 11(68.8) 5 0.044 3(18.8) 13 0.627 14(87.5) 2 0.355 Age                     ≤50 31 26(83.9) 5   6(19.4) 25   25(80.6) 6   >50 62 54(87.1) 8 0.448 12(19.4) 50 0.602

50(80.6) 12 0.616 HBsAg                     Positive 79 71(89.9) 8   16(20.3) 63   63(79.7) 16   Negative 14 9(64.3) 5 0.024 2(14.3) 12 0.461 12(85.7) 2 0.461 AFP(IU/ML)                     ≤400 47 39(83.0) 8   5(10.6) 42   39(83.0) 8   >400 46 41(89.1) 5 0.290 13(28.3) 33 0.029 36(78.3) 10 0.377 Tumor number                     Single 29 26(89.7) 3   2(6.9) 27   23(79.3) 6   >1 64 54(84.4) 10 0.371 16(25.0)

48 0.033 selleckchem 52(81.3) 12 0.516 Tumor size(cm)                     ≤5 16 13(81.3) 3   4(25.0) 12   13(81.3) 3   >5 77 67(87.0) 10 0.394 14(18.2) 63 0.373 62(80.5) 15 0.627 Differentiation                     High 26 26(100) 0   7(26.9) 19   21(80.8) 5   Middle 45 38(84.4) 7   6(13.3) 39   35(77.8) 10   Low 22 16(72.7) 6 0.023 5(22.7) 17 0.340 19(86.4) 3 0.705 Child-Pugh                     A 82 70(85.4) 12   14(17.1) 68   64(78.0) 18   B 11 10(90.9) 1 0.523 4(36.4) 7 0.134 11(100) 0 0.080 BCLC                     B 20 15(75.0) 5   2(10.0) 18   13(65.0) 7   C 73 65(89.0) 8 0.111 16(21.9) 57 0.194 62(84.9) 11 0.051 Hepatic cirrhosis                     Yes 48 45(93.8) 3   5(10.4) 43   37(77.1) 11   No 45 35(77.8) 10 0.026 13(28.9) 32 0.023 38(84.4) 7 0.263 Ascites                     Yes 19 17(89.5) 2   3(15.8) 16   17(89.5) ADP ribosylation factor 2

  No 74 63(85.1) 11 0.476 15(20.3) 59 0.470 58(78.4) 16 0.228 Tumor thrombus                     Yes 38 33(86.8) 5   10(26.3) 28   34(89.5) 4   No 55 47(85.5) 8 0.551 8(14.5) 47( 0.126 41(74.5) 14 0.061 Extrahepatic metastasis                     Yes 48 43(89.6) 5   8(16.7) 40   40(83.3) 8   No 45 37(82.2) 8 0.235 10(22.2) 35 0.339 35(77.8) 10 0.339 VEGFR-2, vascular endothelial growth factor receptor-2; PDGFR-β, platelet-derived growth factor receptor-β; C-MET, hepatocyte growth factor receptor; HbsAg, hepatitis B surface antigen; AFP, serum alpha-fetoprotein; BCLC, Barcelona Clinic Liver Cancer stage.

aureus peptidoglycan. Through this analysis, we identified the 16-kDa C-terminal region as the minimum portion of ORF56 required for bactericidal activity. This 16-kDa protein (Lys16) containing the CHAP domain was purified and found to be stable. Adding 100 μg/ml purified Lys16 to MRSA clinical isolates reduced cell numbers by 99.9%, demonstrating its antibacterial property (Figure 2).

Using antibodies against Lys 16, we were able to localize BAY 63-2521 nmr the protein on the phage tail structure. CHAP domains are present in a wide variety of proteins, including phage endolysins, bacterial autolysins, and various eukaryotic proteins. Most proteins that contain a CHAP domain function are peptidoglycan hydrolases and are associated with amidases [35, 40]. No other known domains were identified in ORF56. Like the tail-associated lysin Tal2009, ORF56 undergoes autoproteolysis upon hyperexpression in an E. coli host [41]. Phage-encoded lytic enzymes typically have a modular organization consisting of a catalytic domain that degrades

the peptidoglycan and a binding R406 domain that recognizes the cell wall of the target bacterium [42]. However, no cell wall-binding domain could be identified in ORF56. NCBI BLAST [27] and Pfam [28] databases were used to compare cell wall targeting/binding domains of various Staphylococcus spp and their phages to select a suitable domain that could be fused to Lys16. Our objective was to generate a chimeric protein with high specificity of target recognition and potent antistaphylococcal activity. To this end, we combined the muralytic LY294002 molecular weight activity of Lys16

with the known specific bacterial cell wall-binding SH3b domain from lysostaphin [23]. The chimeric protein P128 displayed higher activity than Lys16 and was found to be potent against S. aureus (Figure 4). P128 was effective on a panel of MRSA ever and methicillin-sensitive S. aureus clinical isolates representing more than 3,000 isolates (Figure 7). In addition, we demonstrated the in vivo efficacy of P128 in a rat S. aureus nasal colonization model (Figure 8). We chose this model because growing evidence points to nasal carriage as the source of S. aureus infections in various clinical and community settings [43–45]. Although topical mupirocin is effective in clearing nasal S. aureus and reducing the incidence of infection, mupirocin resistance is limiting its preventative and therapeutic use [46, 47]. In our study, we used USA300, which is a community-acquired mupirocin-resistant MRSA strain of high clinical significance [48]. To our knowledge, this is the first report of USA300 use in a nasal colonization model. P128 applied to rat nares in the form of an aqueous gel either decolonized the nares of USA300 completely or significantly reduced cell numbers. Thus, P128 is a novel chimeric protein with potent antistaphylococcal activity and warrants further development for therapeutic use.

bronchiseptica infection 2 days before infection with S. suis; CD caesarean-derived germfree piglets; SPF specific pathogen free piglets; 1 mean number of observations of nervous signs and lameness in one or more joints/total number of observations × 100%; 2 mean number of observations of inappetence and depression/total number of observations × 100%; Path. Pathology: number of pigs with pathological abnormalities; Bact. Bacteriology: Number of piglets from which S. suis is reisolated; NA, animals survived until the end of the experiment; CNS Central nervous system. In the third experiment, specific

pathogen free (SPF) piglets with the age of 6 weeks were infected intranasally with S. suis serotype 9 isolates (1 × 109 CFU) without prior predisposition to B. bronchiseptica. Piglets were kept in sternal position and forced to inhale an aerosol see more produced by an airbrush (Badger, Franklin Park, USA) after anaesthesia with 50% O2/50% N2O/3% halothane. In all experiments, piglets were followed clinically with special regard to signs of meningitis and arthritis. Swabs for bacteriological examination were taken daily from the oropharynx and faeces. Pigs were killed either moribund or 18 days post infection at the end of the observation period by intravenous injection of pentobarbiturate followed by exsanguination and necropsy. Tissue specimens from the central nervous system (CNS),

serosae, Salubrinal and joints were examined bacteriologically and histologically [21, 23]. Multi Locus Sequence

Typing (MLST) MLST was performed as isometheptene described by King et al. [24]. Alternative primers for mutS were used as described previously by Rehm et al. [25]. Chromosomal DNA was isolated from stationary growing bacteria as described previously [26]. PCR reactions were performed using Taq PCR Core kit (QIAgen, Hilden, Germany) according to the manufacturer’s instructions, using 5 μl of diluted (1:100) chromosomal DNA as template, containing at least 350 ng of DNA. PCR products were visually inspected on 1% agarose gels containing ethidium bromide, and subsequently purified and sequenced by Macrogen (Macrogen, Seoul, Korea). Sequence data were analyzed using Lasergene software (DNAstar, Madison, USA). MLST alleles and resulting STs were assigned using the database on http://​ssuis.​mlst.​net/​. New alleles and STs were assigned by the curator of the database. Enzalutamide cost Analysis of ST complexes was performed with eBURST http://​www.​mlst.​net[27]. S. suis oligoarray A S. suis oligoarray (8 × 15 K) containing in situ synthesized 60-mers was produced by Agilent Technologies (Santa Clara, USA), according to a custom probe design based on the genome sequence of S. suis P1/7 [7]. A total of 7651 unique 60-mers having a theoretical melting temperature of approximately 81°C and representing 1960 ORFs were selected as described by Saulnier et al. [28].

Thirdly, the main C-shaped rod in B. bacati is formed by a highly novel arrangement of tightly packed lamellae, and only a single row of microtubules originating from the VR separates the main C-shaped rod from the folded accessory rod. This row of microtubules demarcates the end of each lamella in the main rod. In all of the previously described euglenozoan species, different rods are formed by different proportions of amorphous material (not parallel lamellae) and microtubules originating from the ventral root of the ventral basal body. Fourthly, the posterior

terminus of the accessory rod in B. bacati participates in the formation of a novel click here cytostomal funnel that extends anteriorly and merges with the subapical vestibulum. The cytostomal funnel presumably closes the connection between the flagellar Erastin cell line pocket and the vestibulum during feeding. Although the cytostomal funnel in B. bacati is likely homologous to the “”vanes”" described in several different phagotrophic euglenids, the unusual ultrastructural features of B. bacati made this inference somewhat tenuous. Nonetheless, the additional “”congregated globular structure”" (CGS) at the posterior end of the main rod in B. bacati is also present in Calkinsia aureus [19]. However, the feeding apparatus in C. aureus lacks conspicuous rods (or vanes) and Cell Cycle inhibitor consists mainly of a feeding pocket reinforced by microtubules from the VR, similar to

the MTR pockets of other euglenozoans (e.g., Petalomonas). Overall, the C-shaped rod apparatus in B. bacati appears to contain some homologous subcomponents with phagotrophic euglenozoans Immune system (e.g., a main rod and a folded accessory rod), but, as highlighted above, this apparatus is novel in most respects. The presence of a highly plastic cell surface, an elaborate feeding apparatus, and brownish bodies, reminiscent of food vacuoles, suggests that B. bacati is capable of engulfing large prey cells such as other eukaryotes [1, 3,

24, 27, 29, 37]; however, this species was never directly observed preying on (relatively large) microeukaryotic cells present in the environment. Nonetheless, the presence of intracellular bacteria surrounded by vacuoles near the feeding pocket indicates that B. bacati actively feeds on bacteria. It is also possible that B. bacati feeds on the rod shaped episymbiotic bacteria that grow over the host surface and into the subapical vestibulum. Extrusomes Tubular extrusomes are present in several members of the Euglenozoa [16, 19, 36] and constitute a synapomorphy for the group. Among the Symbiontida, C. aureus has tubular extrusomes clustered in a single large battery that is longitudinally arranged and anchored to a novel “”extrusomal pocket”" [19]. Although Bihospites bacati also possesses tubular extrusomes, these organelles are not organized as a single battery. The extrusomes in B.

1) . Phys Rev B 2001, 63:113104.CrossRef 15. Berggold K, Kriener M, Zobel C, Reichl A, Reuther M, Müller R, Freimuth A, Lorenz T: Thermal conductivity, thermopower, and figure of merit of La 1− x Sr x Co 3 . Phys Rev B 2005, 72:155116.CrossRef 16. Culebras M, Gomez C, Gomez A, Sapina F, Cantarero A: Synthesis of Nd 1− x Ca x CoO 3 perovskite nanowires for thermoelectric applications . J Elect Eng 2:59–64. 17. Park K, Lee GW: Thermoelectric properties of Ca 0.8 Dy 0.2 MnO 3 synthesized by solution combustion process . Nanoscale Res Lett 2011, 6:548. 10.1186/1556-276X-6-548CrossRef 18. Hicks LD, Dresselhaus OSI-906 cell line MS: Effect of quantum-well structures on the thermoelectric figure of merit . Phys Rev B 1993,47(19):12727–12731.

10.1103/PhysRevB.47.12727CrossRef 19. Humphrey TE, Linke H: Reversible thermoelectric nanomaterials . Phys Rev Lett 2005, 94:096601.CrossRef 20. Wang Y, Fan HJ: Improved thermoelectric properties of La 1− x Sr x CoO 3 nanowires . J Phys Chem C 2010,114(32):13947–13953. 10.1021/jp105367rCrossRef 21. Zhang T, Jin C, Qian T, Lu X, Bai J, Li X: Hydrothermal synthesis of single-crystalline La 0.5 Ca 0.5 MnO 3 nanowires at low temperature . J Mater Chem 2004,14(18):2787–2789. 10.1039/b405288aCrossRef 22. Zhu X,

Wang J, Zhang Z, Zhu J, Zhou S, Liu Z, Ming N: Perovskite Selleckchem LCZ696 nanoparticles and nanowires: microwave-hydrothermal synthesis and structural characterization by high-resolution transmission electron microscopy . J Am Ceram Soc 2008,91(8):2683–2689. 10.1111/j.1551-2916.2008.02494.xCrossRef 23. Van Der Pauw LJ: A method of measuring the resistivity and Hall coefficient on lamellae of arbitrary shape . Philips Tech Rev 1958, 20:220–224. 24. de Boor J, Schmidt V: Complete characterization of thermoelectric materials by a combined van der Pauw approach . Adv Mater 2010,22(38):4303–4307. 10.1002/adma.201001654CrossRef 25. Deng J, Zhang L, Dai H, He H,

Au CT: Single-crystalline La 0.6 Sr 0.4 CoO 3− δ nanowires/nanorods derived hydrothermally without the use of a template: catalysts highly active for toluene complete oxidation . Catal Lett 2008,123(3–4):294–300.CrossRef 26. Mahendiran R, Tiwary S, Raychaudhuri A, Ramakrishnan T, Mahesh R, Rangavittal N, Rao C: Structure, electron-transport properties, buy Paclitaxel and giant magnetoresistance of hole-doped LaMnO 3 systems . Phys Rev B 1996,53(6):3348–3358. 10.1103/PhysRevB.53.3348CrossRef 27. Mizusaki J, Yonemura Y, Kamata H, Ohyama K, Mori N, Takai H, Tagawa H, Dokiya M, Naraya K, Sasamoto T, Inaba H, Hashimoto T: Electronic conductivity, Seebeck coefficient, defect and electronic YAP-TEAD Inhibitor 1 Structure of nonstoichiometric La 1− x Sr x MnO 3 . Solid State Ion 2000,132(3–4):167–180.CrossRef 28. Shimura T, Hayashi T, Inaguma Y, Itoh M: Magnetic and electrical properties of La(y)A(x)Mn(w)O(3) (A = Na, K, Rb, and Sr) with perovskite-type structure . J Solid State Chem 1996,124(2):250–263. 10.1006/jssc.1996.0234CrossRef 29.

For advanced limb STSs with large tumor mass, distinct local infiltration or post-surgical relapse, chemotherapy or radiotherapy

combined with surgery is often the first choice [5–7]. Apart from reducing tumor volume, chemotherapy before surgery can also produce a reaction zone between the tumor and peripheral tissues, which serves as an operational tissue space for surgery. However, it remains unclear whether comprehensive treatment schemes using novel chemotherapy regimens could improve the treatment results and prognoses for advanced limb STS [8]. In the present study, we compared pre-operative chemotherapy with oxaliplatin and dacarbazine to the traditional pre-operative VAC treatment, with the hopes of determining it’s safety and to assess whether this regimen imparts a greater advantage, in terms of reducing the tumor margin and PI3K inhibitor LY3039478 increasing progression free survival. Patients and Vadimezan price Methods Inclusion Criteria ① Between 14 years and 70 years of age. ② Female patients that were pregnant or lactating were excluded. ③ No history of chronic primary organ disease, heart failure or other major organ malfunction. ④ The sarcoma originated in limb soft tissue. ⑤ Belong to G1-3T3N0M0 or G1-3T1-3N0-1M1, that is, stage IV according to the Russell GTNM staging system. ⑥ No prior chemotherapy or radiation therapy. Patients Between November 2005 and November 2008, the Department of Surgical Oncology of

Zhejiang Provincial Hospital in China received and treated 31 patients with stage IV limb STS. 15 of these were randomly assigned to the experimental group, and the remaining 16 were assigned to the control group. Patients aged between 18 and 66, with a median age of 41 in the experimental group and 50 in the control group (t = -0.858, p > 0.05). The average tumor size for each group was determined to be in the T3 range (for infiltrating the peripheral vessel, nerve or skeleton). The mean tumor size was 8.4 ± 2.8 cm in the experimental group, and 7.2 ± 1.8 cm (t = 1.453, p > 0.05). In the experimental group, two patients

were diagnosed with regional lymph node metastasis, 2 with why lung metastasis. In the control group, 3 patients were diagnosed with regional lymph node metastasis, and 1 with lung metastasis in the control group, the difference in the prevalence of metastases was not significant (χ2 = 0.011, p > 0.05). Table 1 shows the clinical characteristics of patients recruited for the study. Table 1 Clinical Characteristics of Patients     Experimental group (cases) Control group (cases) Tumor location upper arm 3 3   Thigh 7 11   lower leg 5 2 Pathological phenotypes malignant fibrous histiocytoma 8 6   rhabdomyosarcoma 3 3   synovial sarcoma 0 4   malignant nerve sheath tumor 1 1   clear cell sarcoma 2 0   unclassifiable 1 2 Cytological grading G2 0 1   G3 15 15 The study was conducted according to Good Clinical Practices and was approved by the local ethics committee. All patients gave written informed consent.

Table 1 Reported and adjusted confirmed scarlet fever cases in the whole Country and in central Taiwan from 2000 to 2006. Category 2000 2001 2002 2003 2004 2005 2006 Nationwide               Reported cases (A) 924 1143 1655 1162 1254 1713 1635 Specimens collected (B) 659 792 1359 964 1100 1614 1594 Sampling rate % (B/A) 71% 69% 82% 83% 88% 94% 97% Laboratory

confirmed cases (C) 511 574 1033 640 759 1132 1130 Positive rate % (C/B) 78% 72% 76% 66% 69% 70% 71% Adjusted confirmed SHP099 cost cases (A × C/B) 716 828 1258 771 865 1201 1159 Central region               Reported cases (A) 161 218 332 197 231 307 357 Specimens collected (B) 129 199 307 182 219 305 355 Sampling rate % (B/A) 80% 91% 92% 92% 95% 99% 99% Laboratory confirmed cases (C) 114 146 260 135 156 216 272 Positive rate % (C/B) 88% 73% 85% 74% 71% 71% 77% Adjusted confirmed cases (A × C/B) 142 160 281 146 165 217

274 % of central region/nationwide 20% 19% 22% 19% 19% 18% 24% Isolates collected for analysis 139 154 273 122 115 174 241 The profiles of weekly reported cases revealed that scarlet fever was more prevalent in the winter and spring seasons (2nd – 25th weeks) in 2000–2006. However, there was a remarkable decrease in the number of cases in the 6th and 7th weeks (Figure 1B). This decrease may be due to the long holiday of the traditional lunar New Year and winter break from school, as it is usually from late-January to mid-February (4th – 7th weeks). The weekly reported number of scarlet fever cases in 2002 was mostly higher than the weekly average from 2000 to 2006 (Figure Selleck Abemaciclib 1B). In 2003, except in the 11th week, the number of weekly reported cases in the first next 16 weeks

was greater than the average. Furthermore, the number of cases GNS-1480 price between the 4th and 9th weeks was even higher than that in 2002. After the 16th week, the number of cases in 2003 was below the overall average and was significantly decreased from the 17th to 24th week (mid-April to mid-June). A lower level of reported cases lasted until the first half of year 2004. In early 2003, a severe acute respiratory syndrome (SARS) outbreak occurred in Taiwan. There were two stages for the SARS epidemic: stage I occurred from late-February to mid-April (9th – 16th week), with scattered sporadic cases, and stage II occurred between mid-April and mid-June (17th – 24th week), with severe nosocomial infections in several hospitals. The dramatic decline of scarlet fever notifications in 2003 occurred during the stage II period of the SARS epidemic. Distribution of emm types among isolates collected in central Taiwan For each year between 2000 and 2006, 115 to 273 isolates were collected for genotyping in central Taiwan (Table 1). A total of 1,218 isolates were characterized to investigate the distribution of emm types. In total, 23 emm types were identified in the isolates. The five most prevalent emm types, accounting for 96.8% of the collection, were emm12 (50.4%), emm4 (23.2%), emm1 (16.4%), emm6 (3.8%) and emm22 (3.

Hepatology 2008, 47:1702–1713.CrossRefPubMed 5. Nishikawa Y, Doi Y, Saracatinib chemical structure Watanabe H, Tokairin T, Omori Y, Su M, Yoshioka T, Enomoto K: Transdifferentiation of mature rat hepatocytes into bile duct-like cells in vitro. Am J Pathol 2005, 166:1077–1088.CrossRefPubMed 6. Watanabe H, Hata M, Terada N, Ueda H, Yamada N, Yamanegi K, Ohyama H, Kakihana M, Okamura H, Nakasho K: Transdifferentiation into biliary ductular cells of hepatocytes transplanted into the spleen. Pathology 2008, 40:272–276.CrossRefPubMed

7. Desmet V, Roskams T, Van Eyken P: Ductular reaction in the liver. Pathol Res Pract 1995, 191:513–524.PubMed 8. Chen YK, Zhao XX, Li JG, Lang S, Wang YM: Ductular proliferation in liver tissues with severe chronic hepatitis B: an immunohistochemical study. World J Gastroenterology 2006, 12:1443–1446. 9. Limaye PB, see more Alarcón G, Walls AL, Nalesnik MA, Michalopoulos GK, Demetris AJ, Ochoa

https://www.selleckchem.com/products/gsk3326595-epz015938.html ER: Expression of specific hepatocyte and cholangiocyte transcription factors in human liver disease and embryonic development. Lab Invest 2008, 88:865–872.CrossRefPubMed 10. Kanz MF, Gunasena GH, Kaphalia L, Hammond DK, Syed YA: A minimally toxic dose of methylene dianiline injures biliary epithelial cells in rats. Toxicol Appl Pharmacol 1998, 150:414–426.CrossRefPubMed 11. Kanz MF, Wang A, Campbell GA: Infusion of bile from methylene dianiline-treated rats into the common bile duct injures biliary epithelial cells of recipient rats. Toxicol Lett 1995, 78:165–171.CrossRefPubMed 12. Duncan

SA: Transcriptional regulation of liver development. Dev Dyn 2000, 219:131–142.CrossRefPubMed 13. Zaret KS, Grompe M: Generation and regeneration of cells of the liver and pancreas. Science 2008, 322:1490–1494.CrossRefPubMed 14. Pontoglio M, Barra J, Hadchouel M, Doyen A, Kress C, Bach JP, Babinet C, Yaniv M: Hepatocyte nuclear factor 1 inactivation results in hepatic dysfunction, phenylketonuria, and renal Fanconi syndrome. Cell 1996, 84:575–585.CrossRefPubMed 15. Li J, Ning G, Duncan SA: Mammalian hepatocyte differentiation requires Clomifene the transcription factor HNF-4alpha. Genes Dev 2000, 14:464–474.PubMed 16. Hayhurst GP, Strick-Marchand H, Mulet C, Richard AF, Morosan S, Kremsdorf D, Weiss MC: Morphogenetic competence of HNF4 alpha-deficient mouse hepatic cells. J Hepatol 2008, 49:384–395.CrossRefPubMed 17. Coffinier C, Gresh L, Fiette L, Tronche F, Schütz G, Babinet C, Pontoglio M, Yaniv M, Barra J: Bile system morphogenesis defects and liver dysfunction upon targeted deletion of HNF1beta. Development 2002, 129:1829–1838.PubMed 18. Clotman F, Lannoy VJ, Reber M, Cereghini S, Cassiman D, Jacquemin P, Roskams T, Rousseau GG, Lemaigre FP: The onecut transcription factor HNF6 is required for normal development of the biliary tract. Development 2002, 129:1819–1828.PubMed 19.

CrossRefPubMed 8. Aneja R, Odoms K, Denenberg AG, Wong HR: Theaflavin, a black tea extract, is a novel anti-inflammatory compound. Crit Care Med 2004, 32:2097–2103.CrossRefPubMed 9. Malm C: Exercise-induced muscle damage and inflammation:

fact or fiction? Acta Cilengitide Physiol Scand 2001, 171:233–239.CrossRefPubMed EX 527 mw 10. Tidball JG: Inflammatory processes in muscle injury and repair. Am J Physiol Regul Integr Comp Physiol 2005, 288:345–353. 11. Powers SK, Jackson MJ: Exercise-induced oxidative stress: cellular mechanisms and impact on muscle force production. Physiol Rev 2008, 88:1243–1276.CrossRefPubMed 12. Cooper CE, Vollaard NBJ, Choueiri T, Wilson MT: Exercise, free radicals and oxidative stress. Biochem Soc Trans 2002, 30:280–285.CrossRefPubMed 13. Yu JG,

Carlsson L, Thornell LE: Evidence for myofibril remodeling as opposed to myofibril damage in human muscles with DOMS: an ultrastructural and immunoelectron microscopic study. Histochem QNZ Cell Biol 2004, 121:219–227.CrossRefPubMed 14. Willoughby DS, McFarlin B, Bois C: Interleukin-6 expression after repeated bouts of eccentric exercise. Intl J Sports Med 2003, 24:15–21.CrossRef 15. Febbraio MA, Pedersen BK: Muscle-derived interleukin 6: mechanisms for activation and possible biological roles. FASEBJ 2002, 16:1335–1347.CrossRef 16. Urso ML, Clarkson RM: Oxidative stress, exercise, and antioxidant supplementation. Toxicology 2003, 89:41–54.CrossRef 17. Clarkson PM, Thompson HS: Antioxidants: what role do they play in physical activity and health? Am J Clin Nutr 2000, 72:637S-646S.PubMed 18. Vassilakopoulos T, Karatza MH, Katsaounou P,

Kollintza A, Zakynthinos S, Roussos C: Antioxidants attenuate the plasma cytokine response to exercise in humans. J Appl Physiol 2003, 94:1025–1032.PubMed 19. Huang MT, Liu Y, Ramji D, Lo CY, Ghai G, Dushenkov S, Ho CT: Inhibitory effects of black tea theaflavin derivatives on 12- O almost -tetradecanoylphorbol-12-acetate-induced inflammation and arachidonic acid metabolism in mouse ears. Mol Nutr Food Res 2006, 50:115–122.CrossRefPubMed 20. Barfield JP, Sells PD, Rowe DA, Hannigan-Downs K: Practice effect on the Wingate anaerobic test. J Strength Cond Res 2002, 16:472–473.PubMed 21. Üçok K, Gökbel H, Okudan N: The load for the Wingate test: according to the body weight or lean body mass. Eur J Gen Med 2005, 2:10–13. 22. Pedersen BK, Steensberg A, Fischer C: Exercise and cytokines with particular focus on muscle-derived IL-6. Exer Immun Rev 2001, 7:18–31. 23. Murase T, Haramizu S, Shimotoyodome A, Tokimitsu I, Hase T: Green tea extract improves running endurance in mice by stimulating lipid utilization during exercise. Am J Physiol Regul Integr Comp Physiol 2006, 290:R1550-R1556.PubMed 24. Shimotoyodome A, Haramizu S, Inaba M, Murase T, Tokimitsu I: Exercise and green tea extract stimulate fat oxidation and prevent obesity in mice. Med Sci Sports Exerc 2005, 37:1884–1892.CrossRefPubMed 25.